Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT165b1 Phase 1 for Malaria
NCT05581641Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Dec 2022
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BNT165b1 in malaria, sponsored by BioNTech SE. Primary endpoints: Number of Participants With Solicited Local Reactions at Day 190, Number of Participants With Solicited Systemic Reactions at Day 190 and 3 more. Started Dec 2022; status: completed.
02
Drugs
BNT165b1
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05581641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581641.